Details

Autor(en) / Beteiligte

• Rosendal, Ebba
• Mihai, Ionut Sebastian
• Becker, Miriam
• Das, Debojyoti
• Frängsmyr, Lars
• Persson, B David
• Rankin, Gregory D
• Gröning, Remigius
• Trygg, Johan
• Forsell, Mattias
• Ankarklev, Johan
• Blomberg, Anders
• Henriksson, Johan
• Överby, Anna K
• Lenman, Annasara
• Moscona, Anne

Titel

Serine Protease Inhibitors Restrict Host Susceptibility to SARS-CoV-2 Infections

Ist Teil von

• mBio, 2022-06, Vol.13 (3), p.e0089222-e0089222

Ort / Verlag

United States: American Society for Microbiology

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• The coronavirus disease 2019, COVID-19, is a complex disease with a wide range of symptoms from asymptomatic infections to severe acute respiratory syndrome with lethal outcome. Individual factors such as age, sex, and comorbidities increase the risk for severe infections, but other aspects, such as genetic variations, are also likely to affect the susceptibility to SARS-CoV-2 infection and disease severity. Here, we used a human 3D lung cell model based on primary cells derived from multiple donors to identity host factors that regulate SARS-CoV-2 infection. With a transcriptomics-based approach, we found that less susceptible donors show a higher expression level of serine protease inhibitors SERPINA1, SERPINE1, and SERPINE2, identifying variation in cellular serpin levels as restricting host factors for SARS-CoV-2 infection. We pinpoint their antiviral mechanism of action to inhibition of the cellular serine protease, TMPRSS2, thereby preventing cleavage of the viral spike protein and TMPRSS2-mediated entry into the target cells. By means of single-cell RNA sequencing, we further locate the expression of the individual serpins to basal, ciliated, club, and goblet cells. Our results add to the importance of genetic variations as determinants for SARS-CoV-2 susceptibility and suggest that genetic deficiencies of cellular serpins might represent risk factors for severe COVID-19. Our study further highlights TMPRSS2 as a promising target for antiviral intervention and opens the door for the usage of locally administered serpins as a treatment against COVID-19. Identification of host factors affecting individual SARS-CoV-2 susceptibility will provide a better understanding of the large variations in disease severity and will identify potential factors that can be used, or targeted, in antiviral drug development. With the use of an advanced lung cell model established from several human donors, we identified cellular protease inhibitors, serpins, as host factors that restrict SARS-CoV-2 infection. The antiviral mechanism was found to be mediated by the inhibition of a serine protease, TMPRSS2, which results in a blockage of viral entry into target cells. Potential treatments with these serpins would not only reduce the overall viral burden in the patients, but also block the infection at an early time point, reducing the risk for the hyperactive immune response common in patients with severe COVID-19.